The Future of Pharma:
How Real-World Evidence & AI Are Shaping Market Access in 2025
Why 2025 Is the Breakthrough Year for Real-World Evidence (RWE)?
In 2025, AI-driven healthcare and real-world data (RWD) are transforming how treatments are evaluated, approved, and accessed across global markets. Traditional clinical trials are no longer enough. Pharma companies are now using Real-World Evidence for Drug Approval to accelerate timelines, cut costs, and improve outcomes.
RWE has become a cornerstone in drug development, value-based care, and health technology assessment (HTA) decisions. From clinical trials to reimbursement, the way medicines reach patients is being reimagined and it’s happening right now.
AI in Healthcare: Powering Smarter RWE Strategies
As artificial intelligence becomes central to drug innovation, pharma companies are leveraging AI-powered RWE platforms to:
- Analyze large-scale, real-world patient data across diverse populations
- Predict treatment outcomes using machine learning algorithms
- Generate real-time insights to support market access submissions
- Identify patient cohorts for clinical trials with unmatched precision
These tools are driving personalized medicine and faster market access strategies like never before.
Patient-Centric Drug Development Through Real-World Data
The rise of patient-generated health data from wearables, apps, and remote monitoring is giving pharma an unprecedented view of the patient journey. In 2025, patient-centric drug development is no longer optional, it’s expected.
Real-world data from patients helps pharma:
- Build inclusive and representative clinical trials
- Capture long-term health outcomes for better post-market safety
- Co-create treatment pathways aligned with real-life patient needs
RWE in Clinical Trials: A New Paradigm
Incorporating RWE into hybrid and decentralized clinical trials is among the top pharma trends of 2025. With growing regulatory support from agencies like the FDA and EMA, RWE is now being used to:
- Supplement or replace control arms in trials
- Provide evidence in rare diseases or small populations
- Reduce trial costs while improving data richness
Why Frankfurt Is the Global Hub for Pharma in 2025
The upcoming Global RWE & Market Access Summit 2025, hosted on October 15–16 in Frankfurt, is set in one of Europe’s leading life sciences and regulatory innovation hubs. Frankfurt provides access to:
- Top-tier regulatory bodies and HTA agencies
- A robust pharmaceutical and biotech ecosystem
- Cutting-edge digital health companies
- Central location for EU, UK, Middle East, and Asian attendees
What to Expect at the Global RWE & Market Access Summit 2025
This is more than a conference—it’s a strategic launchpad for the future of pharma. Key features include:
- Expert panels on AI in RWE and healthcare data analytics
- Case studies on market access for rare diseases
- Fireside chats with HTA decision-makers
- Live demos from leading RWD solution providers
- Interactive workshops on pricing, reimbursement, and regulatory strategy
Confirmed speakers include leaders from Gilead, Merck, UCB, EFPIA, and AI health platforms.
Who Should Attend?
- Pharma & Biotech Executives
- Market Access & HEOR Leaders
- RWE and Data Science Experts
- Regulatory Affairs Professionals
- Healthcare Innovators & Solution Providers
Whether you’re launching a therapy, scaling market access, or pioneering data innovation, this is your stage.
Sponsorship & Workshop Opportunities
We’re offering select solution providers the chance to:
- Host branded workshops on trending RWE and AI topics
- Schedule 1:1 meetings with 15+ pre-selected target companies
- Gain brand visibility to over 6,000+ healthcare professionals
- Be featured in digital campaigns and video interviews
If your company specializes in healthcare AI, RWD/RWE platforms, market access consulting, or data analytics, this is your opportunity to lead the conversation.